Search Results - "PierFranco Conte"

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer by André, Fabrice, Ciruelos, Eva, Rubovszky, Gabor, Campone, Mario, Loibl, Sibylle, Rugo, Hope S, Iwata, Hiroji, Conte, Pierfranco, Mayer, Ingrid A, Kaufman, Bella, Yamashita, Toshinari, Lu, Yen-Shen, Inoue, Kenichi, Takahashi, Masato, Pápai, Zsuzsanna, Longin, Anne-Sophie, Mills, David, Wilke, Celine, Hirawat, Samit, Juric, Dejan

“…PIK3CA mutations occur in approximately 40% of patients with hormone receptor–positive breast cancer. A PI3K inhibitor, alpelisib, combined with fulvestrant…”
Get full text

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation by Robson, Mark, Im, Seock-Ah, Senkus, Elżbieta, Xu, Binghe, Domchek, Susan M, Masuda, Norikazu, Delaloge, Suzette, Li, Wei, Tung, Nadine, Armstrong, Anne, Wu, Wenting, Goessl, Carsten, Runswick, Sarah, Conte, Pierfranco

“…Among patients with metastatic breast cancer and a germline BRCA mutation, daily treatment with the PARP inhibitor olaparib was associated with longer…”
Get full text

Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer by Pasello, Giulia, Pavan, Alberto, Attili, Ilaria, Bortolami, Alberto, Bonanno, Laura, Menis, Jessica, Conte, PierFranco, Guarneri, Valentina

“…•Immunotherapy changed treatment paradigm for NSCLC patients.•Real-world patients often differ from selected patients enrolled in clinical trials.•Some patient…”
Get full text

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations by Paik, Paul K, Felip, Enriqueta, Veillon, Remi, Sakai, Hiroshi, Cortot, Alexis B, Garassino, Marina C, Mazieres, Julien, Viteri, Santiago, Senellart, Helene, Van Meerbeeck, Jan, Raskin, Jo, Reinmuth, Niels, Conte, Pierfranco, Kowalski, Dariusz, Cho, Byoung Chul, Patel, Jyoti D, Horn, Leora, Griesinger, Frank, Han, Ji-Youn, Kim, Young-Chul, Chang, Gee-Chen, Tsai, Chen-Liang, Yang, James C.-H, Chen, Yuh-Min, Smit, Egbert F, van der Wekken, Anthonie J, Kato, Terufumi, Juraeva, Dilafruz, Stroh, Christopher, Bruns, Rolf, Straub, Josef, Johne, Andreas, Scheele, Jürgen, Heymach, John V, Le, Xiuning

“…In a study involving patients with non–small-cell lung cancer with a MET exon 14 skipping mutation, the use of tepotinib (a selective MET inhibitor) was…”
Get full text

Evolution of HER2-low expression from primary to recurrent breast cancer by Miglietta, Federica, Griguolo, Gaia, Bottosso, Michele, Giarratano, Tommaso, Lo Mele, Marcello, Fassan, Matteo, Cacciatore, Matilde, Genovesi, Elisa, De Bartolo, Debora, Vernaci, Grazia, Amato, Ottavia, Conte, PierFranco, Guarneri, Valentina, Dieci, Maria Vittoria

“…About a half of HER2-negative breast cancer (BC) show HER2-low expression that can be targeted by new antibody-drug conjugates. The main aim of this study is…”
Get full text

Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy by BASELGA, José, GELMON, Karen A, FUMOLEAU, Pierre, GIANNI, Luca, VERMA, Shailendra, WARDLEY, Andrew, CONTE, Pierfranco, MILES, David, BIANCHI, Giulia, CORTES, Javier, MCNALLY, Virginia A, ROSS, Graham A

“…PURPOSE; Pertuzumab, a human epidermal growth factor receptor 2 (HER2) -targeted monoclonal antibody, potently inhibits HER2 dimerization and HER-mediated…”
Get full text

Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer by Zulato, Elisabetta, Attili, Ilaria, Pavan, Alberto, Nardo, Giorgia, Del Bianco, Paola, Boscolo Bragadin, Andrea, Verza, Martina, Pasqualini, Lorenza, Pasello, Giulia, Fassan, Matteo, Calabrese, Fiorella, Guarneri, Valentina, Amadori, Alberto, Conte, PierFranco, Indraccolo, Stefano, Bonanno, Laura

“…Background Liquid biopsy has the potential to monitor biological effects of treatment. KRAS represents the most commonly mutated oncogene in Caucasian…”
Get full text

Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study by GUARNERI, Valentina, FRASSOLDATI, Antonio, UNTCH, Michael, ORLANDO, Laura, ARTIOLI, Fabrizio, BONI, Corrado, GIULIO GENERALI, Daniele, SERRA, Patrizia, BAGNALASTA, Michela, MARINI, Luca, PIACENTINI, Federico, D'AMICO, Roberto, BOTTINI, Alberto, CONTE, Pierfranco, CAGOSSI, Katia, BISAGNI, Giancarlo, SARTI, Samanta, RAVAIOLI, Alberto, CAVANNA, Luigi, GIARDINA, Giovanni, MUSOLINO, Antonino

“…This is a noncomparative, randomized, phase II trial of preoperative taxane-anthracycline in combination with trastuzumab, lapatinib, or combined trastuzumab…”
Get full text

A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology by Candini, Olivia, Grisendi, Giulia, Foppiani, Elisabetta Manuela, Brogli, Matteo, Aramini, Beatrice, Masciale, Valentina, Spano, Carlotta, Petrachi, Tiziana, Veronesi, Elena, Conte, Pierfranco, Mari, Giorgio, Dominici, Massimo

“…Tumors develop within complex cell-to-cell interactions, with accessory cells playing a relevant role starting in the early phases of cancer progression. This…”
Get full text

LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer by Bonanno, Laura, Zulato, Elisabetta, Pavan, Alberto, Attili, Ilaria, Pasello, Giulia, Conte, PierFranco, Indraccolo, Stefano

“…Liver kinase B1 ( ) is a tumor suppressor gene whose inactivation is frequent in different tumor types, especially in lung adenocarcinoma (about 30% of cases)…”
Get full text

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer by THOMAS, Eva, TABERNERO, Josep, BASELGA, José, RIVERA, Edgardo, GUARNERI, Valentina, POULART, Valerie, KLIMOVSKY, Judith, LEBWOHL, David, MARTIN, Miguel, FORNIER, Monica, CONTE, Pierfranco, FUMOLEAU, Pierre, LLUCH, Ana, VAHDAT, Linda T, BUNNELL, Craig A, BURNS, Howard A, VIENS, Patrice

“…Ixabepilone (BMS-247550) is an epothilone analog that optimizes the properties of naturally occurring epothilone B. Natural epothilones and their analogs…”
Get full text

Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer by Spano, Carlotta, Grisendi, Giulia, Golinelli, Giulia, Rossignoli, Filippo, Prapa, Malvina, Bestagno, Marco, Candini, Olivia, Petrachi, Tiziana, Recchia, Alessandra, Miselli, Francesca, Rovesti, Giulia, Orsi, Giulia, Maiorana, Antonino, Manni, Paola, Veronesi, Elena, Piccinno, Maria Serena, Murgia, Alba, Pinelli, Massimo, Horwitz, Edwin M., Cascinu, Stefano, Conte, Pierfranco, Dominici, Massimo

“…Pancreatic ductal adenocarcinoma (PDAC) is still one of the most aggressive adult cancers with an unacceptable prognosis. For this reason novel therapies…”
Get full text

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer by CORTES, Javier, FUMOLEAU, Pierre, SALVAGNI, Stefania, SERVENT, Veronique, GIANNI, Luca, SCALTRITI, Maurizio, ROSS, Graham A, DIXON, Joanna, SZADO, Tania, BASELGA, José, VALERIA BIANCHI, Giulia, PETRELLA, Teresa M, GELMON, Karen, PIVOT, Xavier, VERMA, Shailendra, ALBANELL, Joan, CONTE, Pierfranco, LLUCH, Ana

“…The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2)…”
Get full text

Metastatic Breast Cancer: Therapeutic Options According to Molecular Subtypes and Prior Adjuvant Therapy by Guarneri, Valentina, Conte, PierFranco

“…In spite of advances in treatment strategies, about 25%–40% of patients with breast cancer still eventually develop metastatic disease that is largely…”
Get full text

Olaparib for the treatment of breast cancer by Griguolo, Gaia, Dieci, Maria Vittoria, Guarneri, Valentina, Conte, PierFranco

Get full text

Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy by Dieci, Maria Vittoria, Griguolo, Gaia, Bottosso, Michele, Tsvetkova, Vassilena, Giorgi, Carlo Alberto, Vernaci, Grazia, Michieletto, Silvia, Angelini, Silvia, Marchet, Alberto, Tasca, Giulia, Genovesi, Elisa, Cumerlato, Enrico, Lo Mele, Marcello, Conte, PierFranco, Guarneri, Valentina

“…Although 1% is the recommended cut-off to define estrogen receptor (ER) positivity, a 10% cut-off is often used in clinical practice for therapeutic purposes…”
Get full text

Immune characterization of breast cancer metastases: prognostic implications by Dieci, Maria Vittoria, Tsvetkova, Vassilena, Orvieto, Enrico, Piacentini, Federico, Ficarra, Guido, Griguolo, Gaia, Miglietta, Federica, Giarratano, Tommaso, Omarini, Claudia, Bonaguro, Serena, Cappellesso, Rocco, Aliberti, Camillo, Vernaci, Grazia, Giorgi, Carlo Alberto, Faggioni, Giovanni, Tasca, Giulia, Conte, Pierfranco, Guarneri, Valentina

“…Tumor-infiltrating lymphocytes (TILs) evaluated in primary breast cancer (BC) convey prognostic information. Limited data in the metastatic setting are…”
Get full text

Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment by Urso, Loredana, Calabrese, Fiorella, Favaretto, Adolfo, Conte, PierFranco, Pasello, Giulia

“…Highlights • p53 is an oncosuppressor protein regulated by MDM2. • p53 might be wild-type in malignant pleural mesothelioma. • MDM2 has p53-independent…”
Get full text

Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane by SPARANO, Joseph A, VRDOLJAK, Eduard, PEREZ MANGA, Gumersindo, PECK, Ronald, POULART, Valerie, CONTE, Pierfranco, RIXE, Oliver, BINGHE XU, MANIKHAS, Alexey, MEDINA, Carlos, VENTILARI DA COSTA, Susanne Crocamo, RO, Jungsil, RUBIO, Gonzalo, RONDINON, Monica

“…We sought to determine whether the combination of ixabepilone plus capecitabine improved overall survival (OS) compared with capecitabine alone in patients…”
Get full text

Adipose-Derived Mesenchymal Stem Cells as Stable Source of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Delivery for Cancer Therapy by GRISENDI, Giulia, BUSSOLARI, Rita, SCARABELLI, Laura, BAMBI, Franco, FRASSOLDATI, Antonio, ROSSI, Giulio, CASALI, Christian, MORANDI, Uliano, HORWITZ, Edwin M, PAOLUCCI, Paolo, CONTE, Pierfranco, DOMINICI, Massimo, CAFARELLI, Luigi, PETAK, Istvan, RASINI, Valeria, VERONESI, Elena, DE SANTIS, Giorgio, SPANO, Carlotta, TAGLIAZZUCCHI, Mara, BARTI-JUHASZ, Helga

“…Adipose-derived mesenchymal stromal/stem cells (AD-MSC) may offer efficient tools for cell-based gene therapy approaches. In this study, we evaluated whether…”
Get full text